JOURNAL OF HEALTH, MEDICAL RESEARCH AND INNOVATIONS

VOLUME: 01 ISSUE: 03 (2023)

P-ISSN : 3105-4749 E-ISSN: 3105-4757

https://www.jhmri.com

Research Article

IMMUNOTHERAPY INNOVATIONS IN CANCER TREATMENT: A NEW ERA OF ONCOLOGY

[1]Dr. Ayesha Khan, [2]Dr. Omar Malik, [3]Prof. Emily Carter, [4]Prof. David Nguyen

[1]Department of Oncology, University of the Punjab, Lahore, Pakistan.
Email: *ayesha.khan@pu.edu.pk*

[2]National Institute of Health, Islamabad, Pakistan.
Email: *omar.malik@nih.gov.pk*

[3]Department of Hematology–Oncology, Johns Hopkins University, Baltimore, USA.
Email: *emily.carter@jhmi.edu*

[4]Department of Molecular Oncology, University College London, UK.
Email: *david.nguyen@ucl.ac.uk*

Abstract:

Cancer immunotherapy has heralded a transformative shift in oncology, leveraging the immune system to achieve durable responses across diverse malignancies. Recent innovations—ranging from checkpoint blockade and CAR-T cell therapies to personalized RNA vaccines, oncolytic viruses, and novel delivery platforms—are extending therapeutic reach into solid tumors and refractory disease. This review synthesizes cutting-edge developments from 2024–2025, emphasizing mechanistic insights, clinical trial outcomes, and delivery innovations. Key challenges—immune evasion, resistance, toxicity, and logistical constraints—are addressed alongside emerging solutions like nanocarriers, biomaterials, and computational multi-omics. This synthesis highlights a new era in immuno-oncology that bridges bench and bedside.

Keywords: *immunotherapy, checkpoint inhibitors, CAR-T cell, RNA vaccine, oncolytic virus, delivery systems, resistance mechanisms, personalized oncology*

Introduction

Recent years have seen immunotherapy emerge from a niche strategy to a foundational pillar in cancer treatment, dramatically changing patient outcomes across melanoma, lung, renal, and hematologic malignancies. Checkpoint inhibitors such as anti-PD-1/PD-L1 have significantly improved survival and progression-free intervals. Adoptive therapies like CAR-T and tumor-infiltrating lymphocyte treatments (e.g., lifileucel) are now FDA-approved—lifileucel for metastatic melanoma emerged in

early 2024. Meanwhile, RNA-based vaccines (e.g., mRNA-4157 in combination therapy) show unprecedented long-term recurrence-free survival. Innovations in delivery—nanoparticles, hydrogels, scaffolds—allow for more controlled and targeted administration. Yet resistance, immune escape, logistics, and adverse effects remain challenging. This article offers a structured overview of these advancements.

Checkpoint Inhibitors: Expansion and Refinement:

Moving Beyond Advanced Disease:

When immune checkpoint inhibitors (ICIs) such as pembrolizumab (anti-PD-1) and atezolizumab (anti-PD-L1) were first introduced, they were restricted to advanced or metastatic cancers where conventional chemotherapy had failed. In the past five years, however, the treatment landscape has **shifted dramatically**:

Neoadjuvant therapy (before surgery): Trials like NADINA in Stage III melanoma have demonstrated that patients receiving nivolumab + ipilimumab prior to surgery had a **higher pathological complete response rate** and **longer relapse-free survival** than those undergoing immediate surgery followed by adjuvant therapy. This shows that early immune priming may help eradicate micrometastases before surgical resection.

Adjuvant therapy (after surgery): Pembrolizumab and nivolumab are now standard of care for high-risk resected melanoma, renal cell carcinoma, and non-small cell lung cancer. Adjuvant immunotherapy reduces recurrence and prolongs overall survival, highlighting a **shift from palliative use to curative intent**.

Combination strategies: Checkpoint inhibitors are increasingly paired with chemotherapy, targeted therapies, or radiotherapy. In lung cancer, chemo-immunotherapy combinations improve both progression-free survival (PFS) and overall survival (OS). In renal cancer, dual immunotherapy (nivolumab + ipilimumab) has outperformed tyrosine kinase inhibitors alone.

Implication: This broadening of indications means checkpoint blockade is **no longer confined to a narrow patient population**, but has become a cornerstone in frontline oncology care.

Biomarker Technologies for Precision Use:

Checkpoint blockade is powerful but not universally effective: **only 20–40% of patients** derive durable benefit depending on tumor type. This has pushed researchers to refine **predictive and monitoring tools**.

Circulating Tumor DNA (ctDNA):

Real-time disease monitoring: ctDNA fragments released by dying tumor cells can be detected in plasma. Falling ctDNA levels during therapy correlate with treatment response, while rising ctDNA predicts resistance weeks before radiological progression.

Minimal Residual Disease (MRD): After surgery, ctDNA can identify patients at risk of relapse. Trials show that MRD-positive patients benefit significantly from adjuvant immunotherapy, while MRD-negative patients may safely avoid unnecessary treatment.

Adaptive immunotherapy: By serially measuring ctDNA, oncologists can escalate or de-escalate checkpoint therapy dynamically—something that static tissue biopsies cannot achieve.

Artificial Intelligence (AI) and Machine Learning:

Predicting responders: AI models trained on **radiomics** (high-dimensional CT/MRI features), **pathology slides**, and **multi-omics data** can stratify patients by likelihood of benefit from checkpoint therapy.

Immune microenvironment analysis: Deep learning can quantify T-cell infiltration, PD-L1 distribution, and stromal features, offering **automated biomarker scoring** that outperforms manual pathology in reproducibility.

Toxicity prediction: AI can integrate patient EHR data, genomics, and lab values to predict risk of **immune-related adverse events (irAEs)** such as colitis or myocarditis, allowing proactive interventions.

Multi-biomarker Panels:

No single biomarker (e.g., PD-L1, TMB, MSI) is sufficient. Current research focuses on **integrated biomarker signatures**:

PD-L1 expression + **TMB (tumor mutational burden)** + **HLA genotype**

ctDNA dynamics + **T-cell receptor repertoire**

Gut microbiome composition (emerging factor linked to immune responsiveness)

These panels, enhanced by AI, aim to deliver a **holistic patient profile** for decision making.

Clinical & Translational Impact:

Personalized immunotherapy: Instead of treating all patients with the same checkpoint drug, therapy is now **tailored to biomarker signatures**, improving outcomes and reducing unnecessary cost/toxicity.

Early intervention: By moving checkpoint inhibitors to earlier stages, oncologists can **cure more patients rather than just prolong life** in metastatic disease.

Dynamic treatment adaptation: ctDNA allows a "liquid biopsy" approach where treatment is adjusted in real time rather than waiting months for imaging.

Global oncology shift: With biomarker-driven patient selection, checkpoint inhibitors are set to dominate **standard protocols in lung, breast, colorectal, melanoma, and genitourinary cancers**. Checkpoint inhibitors are no longer "last-line options." Their role has expanded into **frontline, neoadjuvant, and adjuvant settings**, supported by **advanced biomarker and AI technologies** that enable precise patient selection, real-time monitoring, and personalized adaptation. Together, these innovations mark a true refinement of immunotherapy, ensuring that its benefits reach the right patient at the right time.

Adoptive Cell Therapies (CAR-T, TIL-Based):

Tumor-Infiltrating Lymphocytes (TILs):

Lifileucel FDA approval (2024):

In February 2024, the U.S. FDA approved **lifileucel**, the first TIL-based therapy, for patients with advanced or metastatic melanoma who had progressed after checkpoint inhibitors. This marked a turning point in cell therapy because it validated the concept that expanding a patient's own infiltrating lymphocytes ex vivo and reinfusing them can induce durable responses.

Mechanism:
TILs are naturally primed to recognize tumor-associated antigens. By harvesting them from tumor tissue, expanding them to billions of cells in IL-2–enriched culture, and re-infusing them after lymphodepletion, clinicians deliver a massive, tumor-specific immune boost.

Clinical outcomes:

Objective response rates with lifileucel have been reported at **31–36%** in heavily pretreated melanoma patients.

Some patients experienced **complete and durable responses**, surviving beyond three years after treatment.

Challenges:

Requires surgical tumor resection to harvest TILs.

Manufacturing is logistically complex and time-intensive (3–6 weeks).

Currently most successful in melanoma; expansion to cervical, lung, and ovarian cancers is under investigation.

CAR-T Cell Therapy Innovations:

CAR-T therapy involves genetically engineering patient T-cells to express synthetic **chimeric antigen receptors (CARs)** that recognize specific tumor antigens. While originally developed for hematological cancers, researchers are now tackling **solid tumors**—a far more complex challenge.

Dual Antigen Targeting:

Traditional CAR-T cells target a **single antigen** (e.g., CD19 in leukemia). However, antigen loss or mutation leads to tumor escape.

Dual or tandem CARs target **two antigens simultaneously** (e.g., CD19 + CD22, HER2 + IL13Rα2).

This reduces relapse risk and increases tumor selectivity, minimizing off-target toxicity.

Armored CAR-T Cells:

"Armored" CAR-Ts are engineered to **secrete cytokines (IL-12, IL-18, IL-21)** or express **dominant-negative receptors** that counter immunosuppressive signals in the tumor microenvironment (TME).

These cytokines **enhance T-cell persistence, overcome exhaustion, and recruit endogenous immunity**.

Example: IL-15–secreting CAR-Ts show enhanced expansion and survival in early-phase trials.

In Situ Programming of CAR-T Cells:

Instead of laborious ex vivo manufacturing, new strategies involve **direct infusion of viral or non-viral vectors** that program T-cells **inside the patient's body**.

This reduces cost, manufacturing time, and expands access.

Lipid nanoparticles delivering CAR-encoding mRNA are under clinical testing and may revolutionize scalability.

Novel Delivery Systems for Solid Tumors:

Solid tumors present challenges: **poor T-cell infiltration, hostile TME, and antigen heterogeneity**.

Regional administration: Direct injection of CAR-T into the tumor bed or cerebrospinal fluid (for brain tumors) enhances local concentration.

Biomaterial scaffolds/hydrogels: Implantable scaffolds can provide a reservoir of CAR-T cells that slowly release into the tumor site.

Oncolytic virus-assisted delivery: Viruses can remodel the tumor microenvironment and create "hot" tumors, allowing CAR-T infiltration.

SynNotch circuits: Synthetic biology enables CAR-T cells that activate only in response to a tumor-specific microenvironment, minimizing off-tumor toxicity.

Translational Outlook:

Beyond blood cancers: CAR-T therapies against **mesothelin, HER2, EGFRvIII, GD2, and MUC1** are under investigation in solid tumors like pancreatic, glioblastoma, and sarcomas.

Persistence and safety: Innovations such as "suicide switches" and transient mRNA-based CARs help manage toxicity.

Cost and accessibility: Streamlined manufacturing and in situ programming could make these therapies globally scalable.

Adoptive cell therapies are rapidly diversifying. **TIL-based therapy (lifileucel)** has broken into mainstream oncology with FDA approval, while **next-generation CAR-Ts** are overcoming resistance, toxicity, and solid tumor barriers through **dual targeting, cytokine armoring, in situ programming, and advanced delivery systems**. Together, these innovations point toward a future where engineered immune cells can be deployed against virtually any cancer.

RNA-Based and Neoantigen Vaccines:

mRNA-4157 + Pembrolizumab: A Landmark in Cancer Vaccination:

Background: mRNA-4157 (also called V940, developed by Moderna and Merck) is a **personalized cancer vaccine**. It encodes up to 34 patient-specific tumor neoantigens identified via next-generation sequencing and bioinformatics.

Mechanism: After intramuscular injection, the mRNA is taken up by dendritic cells, which then express the encoded neoantigens, prime T cells, and generate a robust, tumor-specific immune response.

Combination with Pembrolizumab:

Checkpoint inhibitors like pembrolizumab (anti-PD-1) release immune "brakes."

When combined with mRNA-4157, T cells primed by the vaccine remain active longer, leading to **synergistic anti-tumor effects**.

Clinical evidence (KEYNOTE-942 trial):

Patients with high-risk resected melanoma receiving mRNA-4157 + pembrolizumab had a **44% reduction in recurrence or death risk** compared to pembrolizumab alone.

At 3 years, recurrence-free survival was nearly **75% vs. 56%** in the monotherapy group.

Published in PMC (2024), this is the strongest proof that **RNA cancer vaccines can work in real-world oncology**.

Broader potential: mRNA-4157 is now being tested in **non-small cell lung cancer, head & neck cancer, and triple-negative breast cancer**, opening the door to multi-cancer applications.

Neoantigen Vaccines: Precision Against Tumor Signatures:

Unlike traditional vaccines that target shared antigens, **neoantigen vaccines** target **unique tumor-specific mutations**.

ELI-002 2P (KRAS-targeting vaccine):

Background: KRAS mutations (esp. G12D, G12R, G12V) are common in **pancreatic ductal adenocarcinoma (PDAC)** and **colorectal cancer (CRC)**. These mutations are usually "undruggable."

Technology:

ELI-002 is a **lipid-conjugated peptide-based vaccine** designed to elicit strong T-cell responses against KRAS mutations.

The "2P" version covers multiple KRAS variants, increasing patient eligibility.

Clinical evidence (AMPLIFY-201 trial):

In patients with **minimal residual disease after surgery/chemotherapy**, ELI-002 achieved **ctDNA clearance in over 80%** of evaluable patients.

KRAS-specific T-cell responses were detected in the majority of vaccinated individuals.

Early results indicate improved **recurrence-free survival**, especially in ctDNA-positive patients.

Significance: ELI-002 demonstrates that vaccines can tackle **driver mutations** once considered untreatable, providing a precision strategy for lethal cancers like pancreatic adenocarcinoma.

Broader Neoantigen Strategies:

Personalized pipelines: Using whole-exome sequencing and bioinformatics, individualized vaccines can be produced within weeks.

Shared neoantigens: Efforts are ongoing to identify common driver mutations (e.g., TP53, EGFR, IDH1) for scalable vaccines.

Delivery platforms: While peptides and proteins are still used, mRNA technology has gained momentum due to **fast design, scalability, and strong immunogenicity**.

Challenges and Refinements:

Tumor heterogeneity: Some tumors shed new mutations rapidly, so targeting a limited set of neoantigens may not be sufficient.

Immune evasion: Tumors can downregulate MHC presentation, reducing vaccine effectiveness.

Manufacturing logistics: Personalized vaccines require sequencing, bioinformatics, and GMP-grade production, which can delay therapy initiation.

Integration with ICIs: Most vaccines perform poorly alone; their future lies in **synergistic use with checkpoint blockade** or **adoptive cell transfer**.

Translational and Clinical Outlook:

Combination therapies: The success of mRNA-4157 with pembrolizumab establishes a blueprint: vaccines prime T cells, ICIs sustain them.

Liquid biopsy monitoring: ctDNA is increasingly used to track response to neoantigen vaccines, as seen with ELI-002.

Toward "off-the-shelf" vaccines: While personalization is powerful, identifying recurrent shared mutations (KRAS, TP53) may allow scalable semi-universal vaccines.

Expanding indications: From melanoma to gastrointestinal, lung, and gynecologic cancers, RNA/neoantigen vaccines are now in >50 active clinical trials worldwide.

RNA-based vaccines like **mRNA-4157** have shown, for the first time, that vaccines can significantly reduce cancer recurrence when combined with checkpoint blockade. Neoantigen vaccines like **ELI-002** provide a precision weapon against **mutations such as KRAS** in notoriously lethal cancers like pancreatic adenocarcinoma. These breakthroughs signal a **new frontier in oncology**, where vaccines are no longer experimental but are becoming integral to standard immunotherapy pipelines.

Oncolytic and Viral-Based Immunotherapies:

Talimogene Laherparepvec (T-VEC): A Pioneer Therapy:

Background:
T-VEC, approved by the U.S. FDA in 2015, is the **first oncolytic virus therapy** for cancer. It is a genetically engineered **herpes simplex virus type-1 (HSV-1)** modified to selectively replicate in tumor cells while sparing normal tissue.

Mechanism of Action:

Selective replication within tumor cells causes **oncolysis** (tumor cell rupture).

Release of tumor antigens stimulates **local and systemic immune responses**.

T-VEC also encodes **GM-CSF (granulocyte-macrophage colony-stimulating factor)**, which recruits dendritic cells and enhances antigen presentation.

Clinical Benefits:

In advanced melanoma, T-VEC achieved **durable response rates (DRR) of 16–20%**, compared to 2% with GM-CSF alone.

Some patients experienced **complete and long-lasting tumor regression**, including untreated distant metastases (a systemic immune effect).

Limitations:

Best efficacy observed in **locally injectable, accessible lesions** (e.g., cutaneous melanoma).

Limited activity in visceral metastases and bulky tumors.

Requires intratumoral injection, which reduces convenience compared to systemic drugs.

Emerging Oncolytic Platforms:

Beyond T-VEC, a new generation of viral-based immunotherapies is being engineered to **enhance potency and systemic activity**.

Diverse Viral Vectors:

Adenoviruses: Strongly immunogenic, easily engineered; used in solid tumors (e.g., prostate, pancreatic).

Vaccinia virus: Historically used in smallpox vaccination; replicates efficiently in tumors.

Reoviruses: Naturally replicate in cells with activated Ras signaling, common in many cancers.

Coxsackievirus (CVA21): Being studied in melanoma and bladder cancer with encouraging early results.

Armed Oncolytic Viruses:

Modern platforms are "armed" with additional **therapeutic genes** to boost immune activation:

Cytokines (IL-2, IL-12, GM-CSF) to recruit T cells.

Checkpoint inhibitor antibodies (anti-PD-1 or anti-CTLA-4) expressed directly in the tumor site.

Bispecific T-cell engagers (BiTEs) to redirect T cells against tumor cells.

Systemic Antitumor Immunity:

One of the most exciting aspects is the **"in situ vaccination effect"**:

Local tumor destruction releases **neoantigens**.

Antigen-presenting cells process these and activate **cytotoxic T cells**.

These T cells then circulate, attacking **distant metastases** (abscopal effect). This systemic response distinguishes oncolytic viruses from standard local therapies.

Combinatorial Strategies:

Oncolytic viruses rarely achieve long-lasting control as monotherapy. Current research focuses on **synergistic use with other immunotherapies**:

Checkpoint inhibitors (PD-1/CTLA-4): Viral-induced inflammation can convert "cold" tumors into "hot" ones, making resistant cancers sensitive to ICIs. Trials combining T-VEC with pembrolizumab show increased overall response rates in melanoma.

CAR-T therapy: Viruses can remodel the tumor microenvironment to improve T-cell infiltration, addressing one of the biggest barriers in solid tumors.

Cancer vaccines: Viral infection amplifies antigen presentation, enhancing vaccine effectiveness.

Challenges & Innovations:

Tumor Accessibility: Viruses delivered intratumorally work well in melanoma but struggle in deep visceral tumors. Research into **systemic delivery** (intravenous administration) is ongoing.

Host Immunity: Pre-existing antiviral immunity (e.g., from prior HSV or adenovirus exposure) may limit efficacy. Strategies include shielding viruses in nanoparticles or using less common viral strains.

Safety: Ensuring selective replication in tumor cells is critical to avoid damage to normal tissue. Advances in genetic engineering have improved safety profiles.

Manufacturing: Large-scale GMP production of live viruses is complex and costly, but essential for widespread adoption.

Future Outlook:

Next-generation viro-immunotherapy: Platforms are being designed to carry **multiple payloads** (cytokines + checkpoint inhibitors + BiTEs), essentially functioning as **"multi-modal immunotherapy factories" inside the tumor.**

Personalization: With advances in genomic profiling, viruses may be tailored to release tumor-specific neoantigens for individualized immune priming.

Beyond melanoma: Trials are ongoing in **glioblastoma, pancreatic cancer, hepatocellular carcinoma, and lung cancer**. Early data suggest that oncolytic viruses may finally extend into hard-to-treat solid tumors.

Oncolytic viral therapies represent a **dual weapon**: directly lysing tumor cells and **transforming the tumor into a vaccine factory**. T-VEC pioneered this field with durable responses in melanoma, while **emerging viral vectors and armed platforms** promise broader systemic activity. Their greatest potential lies in **combinatorial regimens**, where viral immune priming enhances checkpoint inhibitors, CAR-T therapies, and vaccines. With genetic engineering advancing rapidly, oncolytic virotherapy is poised to become a **central pillar of next-generation immuno-oncology**.

Next-Generation Delivery Platforms & Mechanistic Insights:

Nanoparticles: Precision Delivery Systems:

Why nanoparticles? Traditional systemic delivery of immunotherapies (checkpoint inhibitors, cytokines, CAR-T adjuncts) often leads to **toxicity** (e.g., cytokine storm, off-target inflammation). Nanoparticles allow precise targeting and controlled release.

Design approaches:

Lipid nanoparticles (LNPs): Used in mRNA vaccines, now being adapted for **cancer RNA vaccines and siRNA-based immunomodulators**.

Polymeric nanoparticles: Biodegradable carriers (PLGA, PEGylated systems) enable sustained release of immune agonists or antigens directly into tumor tissue.

Inorganic nanoparticles (gold, iron oxide, silica): Function as delivery systems and imaging agents, allowing **theranostics** (therapy + diagnostics).

Clinical implication: LNPs delivering **mRNA-encoded cytokines or tumor antigens** can transform a cold tumor into a hot one by recruiting immune cells locally, reducing systemic toxicity.

Hydrogels and Biomaterial Scaffolds:

Hydrogels:

Injectable, biodegradable gels that **encapsulate cytokines, checkpoint inhibitors, or immune cells** and slowly release them in situ.

Example: Injectable hydrogels delivering IL-15 superagonists directly into solid tumors, boosting **local NK and CD8+ T-cell activity**.

Biomaterial scaffolds:

3D porous scaffolds implanted near tumor sites can serve as "immune niches," continuously releasing antigens and adjuvants.

They can also act as **T-cell factories**, expanding immune cells in vivo before migration to tumors.

Toxicity reduction: By confining immune stimulation to the tumor bed, biomaterials **minimize systemic cytokine release**, addressing one of the main barriers in CAR-T and cytokine therapies.

Mechanistic Insights via Multi-Omics:

Despite advances, **resistance to immunotherapy** remains a major obstacle. Multi-omics approaches provide deep mechanistic insights:

Genomics: Identifies tumor mutations (e.g., JAK1/2 loss, β2-microglobulin mutations) that confer resistance to checkpoint blockade.

Transcriptomics: Captures expression of immune suppressive pathways (e.g., TGF-β, VEGF signaling).

Proteomics & Metabolomics: Reveal changes in tumor metabolism (e.g., tryptophan–kynurenine axis via IDO1) that suppress T-cell activity.

Spatial multi-omics: Map immune cell localization and activity within the tumor microenvironment (TME).

Artificial Intelligence and Computational Models:

BDVAE Models (Bayesian Deep Variational Autoencoders):

These models integrate high-dimensional omics datasets (DNA, RNA, epigenetics, proteomics) to uncover **hidden features of resistance**.

BDVAE can cluster patients into subgroups predicting who will respond to checkpoint inhibitors vs. who will relapse.

AI-driven predictions:

Radiomics + pathology AI: Analyze CT/MRI scans and digital slides to detect microenvironment patterns linked to resistance.

Longitudinal modeling: AI algorithms track ctDNA + RNAseq over time to forecast **when resistance will emerge**, allowing earlier therapy adaptation.

Clinical translation: These tools support **precision immunotherapy**, tailoring not only the drug but also the **delivery platform** (e.g., hydrogel vs. systemic infusion) to each patient.


Future Perspective:

Smart biomaterials: Nanoparticles/hydrogels embedded with AI-linked biosensors could autonomously regulate drug release in response to local tumor signals (pH, hypoxia, cytokine levels).

Personalized delivery: Multi-omics + AI could determine the optimal **drug formulation and delivery route** for each patient.

Integration with cell therapy: Biomaterial depots may serve as **local expansion hubs for CAR-T or TILs**, reducing the need for extensive ex vivo manufacturing.

Next-generation delivery platforms — **nanoparticles, hydrogels, and scaffolds** — are transforming immunotherapy by enhancing **spatial precision** and reducing systemic toxicity. Simultaneously, **multi-omics data integrated with AI (e.g., BDVAE models)** are uncovering the **mechanisms of resistance**, enabling proactive patient stratification and therapy adaptation. Together, they mark a **technological revolution in immuno-oncology**, bringing personalized, safer, and more durable cancer immunotherapies within reach.



Summary:

Immunotherapy's evolution reflects a paradigm shift in oncology, transitioning from broad-based approaches to highly personalized, mechanism-driven modalities. From checkpoint blockade to cellular therapies, RNA vaccines, and innovative delivery systems, the diversity of strategies now brings real hope for durable remission. Addressing resistance and cost, leveraging computational tools, and improving access will be critical steps forward. As recent clinical successes and approval milestones illustrate, the "molecular immune era" of cancer care is well underway.

References:

Zhang M. Advances in cancer immunotherapy: historical perspectives. Molecular Cancer (2025).

Hsu CY. Innovations in cancer immunotherapy: A comprehensive review. (2024).

Emens LA. Challenges and opportunities in cancer immunotherapy. (2024).

Magoola M. Current progress and future perspectives of RNA-based cancer vaccines. (2025).

Maccagno M. Emerging immunotherapies: CAR-T and bispecific antibodies. (2024).

Ascertain innovations presented at ASCO 2025. Cancer Therapy Advisor.

Desai I. Current advances in immunotherapy for cancer. (2024).

Fayyaz A. Personalized biological therapies in oncology. (2024).

Bandara S. Current landscape and future directions in cancer immunotherapy. (2025).

Sharma K. Innovations in immunotherapy drug delivery platforms. (2025).

Liu B. Treatment modalities including immunotherapy and gene therapy. (2024).

Frontiers review of predictive biomarkers in SCLC immunotherapy.

Lifileucel approval and clinical details.

CAR-T developments and delivery strategies.

Cryoimmunotherapy combining cryoablation with immunotherapy.

T-VEC as approved oncolytic virus for melanoma.

ELI-002 2P KRAS vaccine trial results.

NAC treatment with Nivolumab + Ipilimumab in Stage 3 melanoma (NADINA trial).

ASCO 2025 highlights: pembrolizumab, lifileucel, CAR-T in solid tumors.

BioNTech's BNT323 HER2-targeted immunotherapy Phase 3 success.